Phase I study to determine the MTD of paclitaxel given three times per week during concurrent radiation therapy for stage III non-small cell lung cancer

Author： Shi Anhui   An Tongtong   Zhu Guangying   Yu Rong   Xu Gang   Liu Xuyi   Xu Bo  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.23, Iss.5, 2007-05, pp. : 1161-1167

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paclitaxel, Carboplatin, and G-CSF in Advanced Non-Small-Cell Lung Cancer: A Phase I/II Study

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1998-09 ,pp. : 310-314

Karger

Access to resources Recommend Favorite

Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients

By  

Oncology, Vol. 91, Iss. 4, 2016-07 ,pp. : 194-204

Karger

Access to resources Recommend Favorite

Surgery versus stereotactic body radiation therapy for stage I non–small cell lung cancer: A comprehensive review

By  

CANCER, Vol. 124, Iss. 4, 2018-02 ,pp. : 667-678

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-07 ,pp. : 435-443

Karger

Access to resources Recommend Favorite

Phase II Study of Weekly Paclitaxel in Patients with Non-Small Cell Lung Cancer Who Have Failed Previous Treatments

By  

Oncology, Vol. 66, Iss. 5, 2004-09 ,pp. : 347-352

Karger

Access to resources Recommend Favorite